NCT03785249: MRTX849 in Patients With Cancer Having a KRAS G12C Mutation

NCT03785249
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: KRAS+
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patient must have tumor(s) with KRAS G12C mutation
Exclusions: Patients with active brain metastases
https://ClinicalTrials.gov/show/NCT03785249

Comments are closed.

Up ↑